From Monday, the first daily GLP-1 weight-loss pills will go on sale in the UK, with pharmacies, supermarkets and online providers reporting extraordinary demand before the 3-a-day pills are even available
Logging symptoms and timing relative to doses helps providers decide if titration adjustments or medication interactions are at play
[13] Dosing at night is thought to mimic the natural physiologic rhythm, as endogenous GH release is highest during sleep
There have been postmarketing reports of acute renal failure (unspecified) and worsening of chronic renal failure, which sometimes has required hemodialysis in patients treated with GLP-1 receptor agonists
This raises important questions about consistency, safety, and the appropriate boundaries of digital prescribing
These studies are conducted strictly for educational and exploratory purposes and are not positioned as peptide therapy